Former Novo Nordisk exec joins ALK Abello as EVP of R&D

Danish allergy immunotherapy specialist ALK Abello (ALKB: DC) today announced that Dr Henriette Mersebach will join the company as executive vice president, research and development and member of the board of management.

Dr Mersebach will replace Henrik Jacobi, who wishes to retire from the position after 22 years with ALK, 19 years of which serving as EVP of R&D. To facilitate a smooth generational change, Dr Jacobi will continue in his present role until Dr Mersebach takes up office, expected on March 1, 2023. After that, Dr Jacobi will become a member of ALK’s scientific committee.

A Danish citizen, Dr Mersebach, will bring extensive experience to ALK from more than 17 years of global clinical and product development work at Novo Nordisk (NOV: N), with responsibility for both early- and late-stage development activities. She currently holds the position as corporate project vice president, rare disease and advanced therapies, being responsible for recent pipeline expansions, building the area, and for leading the organizational development. Prior to joining Novo Nordisk, Dr Mersebach worked as a medical doctor, amongst other with clinical experience in paediatrics.